Is Cabozantinib currently included in the medical insurance reimbursement list?

Cabozantinib (Cabozantinib) has not yet been officially launched in China, and therefore has not been included in the national medical insurance reimbursement catalog. This means that domestic patients are temporarily unable to enjoy the cost reimbursement of the drug through medical insurance policies, and purchase channels are relatively limited. For patients who need to use cabozantinib, they usually need to purchase the drug through formal overseas channels.

In overseas markets, cabozantinib has various versions of the original drug, including European, Hong Kong, Japanese and Turkish versions. The price range is wide, generally between more than 20,000 yuan to more than 50,000 yuan. The cost is relatively expensive, which brings certain financial pressure to patients. Original drugs have won the trust of patients with their high quality and strict drug supervision, but their high prices limit their use by some patients.

In comparison, there are already regular cabozantinib generics on the market in Laos and Bangladesh. The ingredients of these generic versions are basically the same as the original drugs, and the specifications include20mg, 90 tablets, There are many options, including pan>60mg 30 tablets, 80mg*30 tablets, etc. The price is obviously affordable, usually ranging from more than 500 yuan to one or two thousand yuan. For patients with limited financial resources, generic drugs offer an affordable and effective alternative.

Overall, cabozantinib is currently not covered by the domestic medical insurance system. If patients want to use it, they need to reasonably choose the purchase method and drug specifications based on their own circumstances. In the future, with the progress of cabozantinib's approval and marketing in China, it is expected to gradually enter the medical insurance system to provide patients with more convenience and protection.

Reference materials:https://www.drugs.com/